알림·소식
알림·소식
[2019 Pasteur Colloquium] Felix Calderon 박사, 트레스 칸토스 오픈랩, GSK Global Health R&D (스페인)
2019-10-17
____________________________________________
[한국파스퇴르연구소] 파스퇴르 콜로퀴엄
일시 : 2019년 10월 18일 (금), 오후 2시
장소 : 모노드 회의실 (1층), 한국파스퇴르연구소
______________________________________________________________________________________________________
.png)
연자
Felix Calderon 박사
트레스 칸토스 오픈랩 책임자, GSK Global Health R&D, 스페인
강연주제
The Tres Cantos Open Lab: Enabling Innovation
for Under-Researched Infectious Diseases
초록
In the belief that partnership is essential in the fight against endemic infectious diseases, GSK launched in 2010 the Tres Cantos Open Lab Foundation (TCOLF). A non-for-profit organization (registered as a UK based charity) overseen by an independent Governing Board (GB) of world leading scientists in the field. The TCOLF was conceived to address the translational and funding gap existing in global health between basic research and drug discovery by creating a project based collaborative environment integrating third parties (academia, biotech, pharma, etc.) and GSK teams. Its uniqueness resides on enable the co-location of open lab fellows within an industry environment.
This co-location has allowed an unprecedented degree of scientific exchange and has triggered numerous follow on grants and activities. To date, some key successes include: development of new platforms, discovery of novel new clinical candidates, identification of new sets of high value hits made available to the wider community and repurposing opportunities of antibiotics to treat drug resistant bacterial infections.
Projects in scope include innovative approaches in the field of endemic infectious diseases that could offer a new solution to an existing gap that can benefit from collaboration with the pharma industry in the fields of gut health (including bacterial enteric infections and environmental enteric dysfunction, EED), malaria, tuberculosis, and kineto mediated infections. In April 2019, the Governing Board agreed to expand the focus of TCOLF to include translational and clinical activities (up to Ph2a), to support the development of advance leads and clinical assets towards their next phase.
During this seminar, the collaborative model supported by the foundation as well as current scientific priorities and opportunities will be presented. In addition, a review of the science behind key programs in the TCOLF pipeline will be also covered.
___________________________________________
*파스퇴르 콜로퀴엄 관련 문의사항은 sukyon.yang@ip-korea.org 로 이메일 송부 부탁드립니다. 연구소 관련 추가 내용은 홈페이지 (www.ip-korea.org) 를 통해 확인하실 수 있습니다.
** 한국파스퇴르연구소 약도: http://www.ip-korea.org/about_us/location.php
[한국파스퇴르연구소] 파스퇴르 콜로퀴엄
일시 : 2019년 10월 18일 (금), 오후 2시
장소 : 모노드 회의실 (1층), 한국파스퇴르연구소
______________________________________________________________________________________________________
연자Felix Calderon 박사
트레스 칸토스 오픈랩 책임자, GSK Global Health R&D, 스페인
강연주제
The Tres Cantos Open Lab: Enabling Innovation
for Under-Researched Infectious Diseases
초록
In the belief that partnership is essential in the fight against endemic infectious diseases, GSK launched in 2010 the Tres Cantos Open Lab Foundation (TCOLF). A non-for-profit organization (registered as a UK based charity) overseen by an independent Governing Board (GB) of world leading scientists in the field. The TCOLF was conceived to address the translational and funding gap existing in global health between basic research and drug discovery by creating a project based collaborative environment integrating third parties (academia, biotech, pharma, etc.) and GSK teams. Its uniqueness resides on enable the co-location of open lab fellows within an industry environment.
This co-location has allowed an unprecedented degree of scientific exchange and has triggered numerous follow on grants and activities. To date, some key successes include: development of new platforms, discovery of novel new clinical candidates, identification of new sets of high value hits made available to the wider community and repurposing opportunities of antibiotics to treat drug resistant bacterial infections.
Projects in scope include innovative approaches in the field of endemic infectious diseases that could offer a new solution to an existing gap that can benefit from collaboration with the pharma industry in the fields of gut health (including bacterial enteric infections and environmental enteric dysfunction, EED), malaria, tuberculosis, and kineto mediated infections. In April 2019, the Governing Board agreed to expand the focus of TCOLF to include translational and clinical activities (up to Ph2a), to support the development of advance leads and clinical assets towards their next phase.
During this seminar, the collaborative model supported by the foundation as well as current scientific priorities and opportunities will be presented. In addition, a review of the science behind key programs in the TCOLF pipeline will be also covered.
*파스퇴르 콜로퀴엄 관련 문의사항은 sukyon.yang@ip-korea.org 로 이메일 송부 부탁드립니다. 연구소 관련 추가 내용은 홈페이지 (www.ip-korea.org) 를 통해 확인하실 수 있습니다.
** 한국파스퇴르연구소 약도: http://www.ip-korea.org/about_us/location.php